Concord Biotech Gets USFDA Nod to Market Multiple Sclerosis Drug

Concord Biotech Ltd on Tuesday said it has received final approval from the US Food and Drug Administration to market Teriflunomide Tablets in 7 mg and 14 mg strengths. The tablets are used to treat patients with relapsing forms of multiple sclerosis, the company said in an exchange filing.

The US market for Teriflunomide tablets is valued at around $402 million, while the global market stands at approximately $908 million, according to data from IQVIA, a global clinical research services provider.

Concord Biotech said this approval opens up strong opportunities to expand in both the US and global markets.